Increased Licensing-In Activities by Domestic Firms

A number of domestic pharmaceutical firms are undertaking the licensing-in activities to introduce competitive products in the domestic ethical medication market, and the industry expects that such introductions will help these companies realize higher sales.

Daewoong Pharmaceutical recently launched Olmetec (olmesartan medoxomil), an anti-hypertensive medication, under an exclusive licensi...